Streetbeat News

Stock Prices

MXROF

Max Iron Brazil Ltd has received in-principle advice from the ASX to proceed with plans for listing on the ASX. This development is part of Max Resource Corp's ongoing efforts to expand its market presence.

Portfolio Pulse from

January 31, 2025 | 5:30 pm

CROX

Shareholders of Crocs, Inc. (CROX) who incurred losses are encouraged to join a class action lawsuit. The lawsuit aims to recover potential losses under federal securities laws.

Portfolio Pulse from

January 31, 2025 | 5:30 pm

QBTS

RGTI

Quantum computing stocks, including Rigetti (RGTI), D-Wave Quantum (QBTS), and IonQ, have shown significant volatility recently. The article discusses whether these stocks are merely experiencing a temporary downturn or if they are facing more serious challenges.

Portfolio Pulse from

January 31, 2025 | 5:30 pm

PLTR

Charles Moon from Prosper Trading Academy discusses the potential of tech stocks, highlighting Palantir (PLTR) as a candidate for significant growth, possibly reaching $100, despite already hitting all-time highs.

Portfolio Pulse from

January 31, 2025 | 5:15 pm

AXSM

Axsome Therapeutics (AXSM) received FDA approval for its new migraine drug, Symbravo, for the acute treatment of migraine in adults. This approval diversifies Axsome's commercial portfolio and has positively impacted its stock price.

Portfolio Pulse from

January 31, 2025 | 5:15 pm

SYM

Levi & Korsinsky has filed a securities class action lawsuit on behalf of Symbotic Inc. (SYM) shareholders. Investors who suffered losses can seek potential recovery under federal securities laws.

Portfolio Pulse from

January 31, 2025 | 5:15 pm

REGN

Investors in Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) who have incurred losses have the opportunity to lead a securities fraud class action lawsuit, as announced by the Law Offices of Frank R. Cruz.

Portfolio Pulse from

January 31, 2025 | 5:15 pm

IBM

IBM's stock surged 13% to a new all-time high after reporting strong Q4 2024 earnings. Investors are considering ETFs to capitalize on this momentum.

Portfolio Pulse from

January 31, 2025 | 5:15 pm

VRTX

Vertex Pharmaceuticals received FDA approval for its non-opioid pain drug, Journavx, aimed at treating moderate-to-severe acute pain in adults. Following the announcement, Vertex's shares experienced an increase.

Portfolio Pulse from

January 31, 2025 | 5:15 pm

BOOM

DMC Global Inc. (NASDAQ: BOOM) investors who have incurred losses have the opportunity to lead a securities fraud class action lawsuit. The deadline to participate as a lead plaintiff is February 4, 2025.

Portfolio Pulse from

January 31, 2025 | 5:15 pm